NMDA antagonists as Parkinson's disease therapy: disseminating the evidence

Zsófia Majláth, L. Vécsei

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Oral levodopa is the current baseline therapy in the management of Parkinson's disease, but nonmotor complications and therapy-related dyskinesias pose an important challenge for clinicians. Glutamate receptors have been implicated in the neurodegenerative process of Parkinson's disease and also in the development of levodopa-induced dyskinesias. This article discusses the role of NMDA receptors in Parkinson's disease and their modulation as a possible therapeutic approach.

Original languageEnglish
Pages (from-to)23-30
Number of pages8
JournalNeurodegenerative disease management
Volume4
Issue number1
DOIs
Publication statusPublished - 2014

Fingerprint

N-Methylaspartate
Parkinson Disease
Dyskinesias
Levodopa
Glutamate Receptors
N-Methyl-D-Aspartate Receptors
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

NMDA antagonists as Parkinson's disease therapy : disseminating the evidence. / Majláth, Zsófia; Vécsei, L.

In: Neurodegenerative disease management, Vol. 4, No. 1, 2014, p. 23-30.

Research output: Contribution to journalArticle

@article{de5c2d5a51884f7e8901a566a4529691,
title = "NMDA antagonists as Parkinson's disease therapy: disseminating the evidence",
abstract = "Oral levodopa is the current baseline therapy in the management of Parkinson's disease, but nonmotor complications and therapy-related dyskinesias pose an important challenge for clinicians. Glutamate receptors have been implicated in the neurodegenerative process of Parkinson's disease and also in the development of levodopa-induced dyskinesias. This article discusses the role of NMDA receptors in Parkinson's disease and their modulation as a possible therapeutic approach.",
author = "Zs{\'o}fia Majl{\'a}th and L. V{\'e}csei",
year = "2014",
doi = "10.2217/nmt.13.77",
language = "English",
volume = "4",
pages = "23--30",
journal = "Neurodegenerative disease management",
issn = "1758-2024",
publisher = "Future Medicine Ltd.",
number = "1",

}

TY - JOUR

T1 - NMDA antagonists as Parkinson's disease therapy

T2 - disseminating the evidence

AU - Majláth, Zsófia

AU - Vécsei, L.

PY - 2014

Y1 - 2014

N2 - Oral levodopa is the current baseline therapy in the management of Parkinson's disease, but nonmotor complications and therapy-related dyskinesias pose an important challenge for clinicians. Glutamate receptors have been implicated in the neurodegenerative process of Parkinson's disease and also in the development of levodopa-induced dyskinesias. This article discusses the role of NMDA receptors in Parkinson's disease and their modulation as a possible therapeutic approach.

AB - Oral levodopa is the current baseline therapy in the management of Parkinson's disease, but nonmotor complications and therapy-related dyskinesias pose an important challenge for clinicians. Glutamate receptors have been implicated in the neurodegenerative process of Parkinson's disease and also in the development of levodopa-induced dyskinesias. This article discusses the role of NMDA receptors in Parkinson's disease and their modulation as a possible therapeutic approach.

UR - http://www.scopus.com/inward/record.url?scp=84921994578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921994578&partnerID=8YFLogxK

U2 - 10.2217/nmt.13.77

DO - 10.2217/nmt.13.77

M3 - Article

C2 - 24640976

AN - SCOPUS:84921994578

VL - 4

SP - 23

EP - 30

JO - Neurodegenerative disease management

JF - Neurodegenerative disease management

SN - 1758-2024

IS - 1

ER -